Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with Graves Disease
- Age-matched healthy checkup subjects
Exclusion Criteria:
- Patients with a medical history of diabetes, pancreatitis and other related conditions and positive family histories as well as medication history of glucocorticoid and anti-diabetic agents
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
GA1
subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
GA2
subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
GA3
subjects from coastal areas who were under Methimazole treatment and with a normal TH level
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
GB1
subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
GB2
subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
GB3
subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
|
All enrolled subjects with GD were treated with methimazole.
The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d.
The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d.
All subjects underwent a treatment course over a period of 6 months.
Other Names:
|
|
NC
age-matched healthy checkup subjects
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change from baseline blood glucose at 6 months
Time Frame: at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
|
change from baseline insulin at 6 months
Time Frame: at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
|
change from baseline thyroid hormone at 6 months
Time Frame: at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
|
change from baseline urine iodine concentration at 6 months
Time Frame: at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
at the day of the subject's enrollment into the study(baseline) and at 6 months after the enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Endocrine System Diseases
- Thyroid Diseases
- Exophthalmos
- Orbital Diseases
- Goiter
- Hyperthyroidism
- Graves Disease
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Antithyroid Agents
- Methimazole
Other Study ID Numbers
Other Study ID Numbers
- GD-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.